With this partnership, we look forward to working with BDLS to strengthen EXICARE’s ability to provide industry knowledge, advice and quality services to our client base.
Tokyo, Japan (PRWEB UK) 8 June 2015
CAC EXICARE Corporation (EXICARE), a leading Japanese Contract Research Organization, today announced a partnership with Business & Decision Life Sciences (BDLS), a Contract Research Organization (CRO) specializing in CDISC Data Standards implementation, conversion and governance, headquartered in Brussels, Belgium.
This partnership enhances EXICARE’s ability to support Japanese pharmaceutical companies prepare for the PMDA mandating CDISC data sets as part of all drug submissions from 2016 onwards.
EXICARE selected BDLS as its CDISC knowledge partner due to BDLS’ eight years of experience in converting and the management of CDISC data in over 650 studies across more than 90 drug submissions.
“EXICARE has a well-deserved reputation for outstanding customer care and commitment to quality.” said Peter Van Reusel, Chief Operating Officer at BDLS. “The partnership is a very positive move for both companies and will allow BDLS and EXICARE to enhance and develop the services we are able to offer to Japanese pharma companies.”
Over the last eight years, BDLS has built a tried-and-tested methodology for converting clinical data into CDISC data standards built upon a SAS Data Integration Studio platform which delivers validated CDISC-compliant data sets that can be included in regulatory submissions. This partnership will allow EXICARE to leverage this experience.
“Business & Decision Life Sciences has a long history of providing excellent service and quality to sponsors and is viewed as a leader in CDISC data standards,” said Koji Iwamoto, General Manager at BTO Department II, EXICARE. “With this partnership, we look forward to working with BDLS to strengthen EXICARE’s ability to provide industry knowledge, advice and quality services to our client base.”
About CAC EXICARE Corporation
CAC EXICARE is a solutions provider that supports pharmaceutical companies in both contract services and IT systems solutions. We will contribute to advancements in medical care and greater health and happiness for individuals by providing exceptional, comprehensive services in pharmaceuticals and healthcare, focused on IT and operational services and founded on high ethical standards.
From drug discovery and non-clinical activities to post-marketing surveillance, we strongly support all the various processes of the pharmaceutical industry with the best use of IT. We therefore hope to be an essential partner for global business expansion of pharmaceutical companies.
We meet the client needs for supports on global business by various activities with our overseas offices. Alliances with domestic and overseas CRO and SMO as well as IT & BPO vendors lead to a strong synergetic effect to respond quickly and flexibly to meet client needs.
CAC EXICARE Website：http://www.exicare.com
About Business & Decision Life Sciences
BDLS is part of the Business & Decision Group, an international consulting and Systems Integration Company founded in 1992 and listed on the Eurolist C exchange.
BDLS is specialized in the delivery of services and provision of solutions in the Life Sciences industry. With 20 years of experience, it supports its clients in the pharmaceutical, medical device, biotechnology, food and cosmetics industries.
Core skills include the provision of a range of expert CRO and consulting services (supporting clinical trials in the operational, data management, analytical, outcome research, and document writing area) and the implementation of technology-based, clinical applications and solutions tailored for the Life Sciences industry.
BDLS is headquartered in Brussels, Belgium and has a strong international presence in five countries in North America and Europe. For more information, visit http://www.businessdecision-lifesciences.com.
CAC EXICARE Corporation
Business & Decision Life Sciences